CA2687931C - Ccr2 receptor antagonists and uses thereof - Google Patents

Ccr2 receptor antagonists and uses thereof Download PDF

Info

Publication number
CA2687931C
CA2687931C CA2687931A CA2687931A CA2687931C CA 2687931 C CA2687931 C CA 2687931C CA 2687931 A CA2687931 A CA 2687931A CA 2687931 A CA2687931 A CA 2687931A CA 2687931 C CA2687931 C CA 2687931C
Authority
CA
Canada
Prior art keywords
amino
phenyl
chloro
methoxy
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2687931A
Other languages
English (en)
French (fr)
Other versions
CA2687931A1 (en
Inventor
Heiner Ebel
Stefan Peters
Silke Hobbie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CA2687931A1 publication Critical patent/CA2687931A1/en
Application granted granted Critical
Publication of CA2687931C publication Critical patent/CA2687931C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2687931A 2007-05-31 2008-05-29 Ccr2 receptor antagonists and uses thereof Active CA2687931C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07109376.9 2007-05-31
EP07109376 2007-05-31
PCT/EP2008/056573 WO2008145681A2 (en) 2007-05-31 2008-05-29 Ccr2 receptor antagonists and uses thereof

Publications (2)

Publication Number Publication Date
CA2687931A1 CA2687931A1 (en) 2008-12-04
CA2687931C true CA2687931C (en) 2016-05-24

Family

ID=38752546

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2687931A Active CA2687931C (en) 2007-05-31 2008-05-29 Ccr2 receptor antagonists and uses thereof

Country Status (8)

Country Link
US (1) US8653262B2 (enExample)
EP (1) EP2155689B1 (enExample)
JP (1) JP5603770B2 (enExample)
AR (1) AR066799A1 (enExample)
CA (1) CA2687931C (enExample)
CL (1) CL2008001593A1 (enExample)
TW (1) TW200904434A (enExample)
WO (1) WO2008145681A2 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202003901UA (en) 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
DE102006039003A1 (de) 2006-08-19 2008-02-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Verbindungen
JP5603770B2 (ja) 2007-05-31 2014-10-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ２受容体拮抗薬およびその使用
KR20150036210A (ko) 2007-06-13 2015-04-07 인사이트 코포레이션 야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염
EP2188269B1 (de) 2007-08-14 2014-05-07 Boehringer Ingelheim International GmbH Arylsulfonamide mit analgetischer wirkung
EP2025675A1 (de) 2007-08-14 2009-02-18 Boehringer Ingelheim International GmbH Arylsulfonamide mit analgetischer Wirkung
WO2009076404A1 (en) * 2007-12-10 2009-06-18 Epix Delaware, Inc. Carboxamide compounds and their use as antagonists of the chemokine ccr2 receptor
KR20110053424A (ko) * 2008-08-12 2011-05-23 베링거 인겔하임 인터내셔날 게엠베하 사이클로알킬-치환된 피페라진 화합물의 제조 방법
US20100113472A1 (en) * 2008-11-03 2010-05-06 Chemocentryx, Inc. Compounds for the treatment of osteoporosis and cancers
CN102256963B (zh) 2008-12-19 2014-06-11 贝林格尔.英格海姆国际有限公司 作为ccr2受体拮抗剂用于治疗炎症、哮喘和copd的环状嘧啶-4-甲酰胺
SI2432472T1 (sl) 2009-05-22 2019-11-29 Incyte Holdings Corp 3-(4-(7H-pirolo(2,3-d)pirimidin-4-il)-1H-pirazol-1-il)oktan- ali heptan-nitril kot inhibitorji JAK
AR076794A1 (es) 2009-05-22 2011-07-06 Incyte Corp Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
ES2674275T3 (es) 2009-12-17 2018-06-28 Centrexion Therapeutics Corporation Antagonistas del receptor CCR2 y usos de los mismos
EP3354652B1 (en) 2010-03-10 2020-05-06 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
JP5646736B2 (ja) 2010-05-12 2014-12-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ｃｃｒ２受容体アンタゴニスト、これらの製造方法、及び薬物としてのこれらの使用
WO2011141474A1 (en) * 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
WO2011144501A1 (en) 2010-05-17 2011-11-24 Boehringer Ingelheim International Gmbh Ccr2 antagonists and uses thereof
PE20130216A1 (es) 2010-05-21 2013-02-27 Incyte Corp Formulacion topica para un inhibidor de jak
WO2011147772A1 (en) 2010-05-25 2011-12-01 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists
US8962656B2 (en) 2010-06-01 2015-02-24 Boehringer Ingelheim International Gmbh CCR2 antagonists
WO2011153359A1 (en) 2010-06-04 2011-12-08 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
PE20140146A1 (es) 2010-11-19 2014-02-06 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
EP2707367B1 (en) * 2011-05-12 2019-10-09 Bionomics Limited Methods for preparing naphthyridines
CN103797010B (zh) 2011-06-20 2016-02-24 因塞特控股公司 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
EP2731941B1 (en) 2011-07-15 2019-05-08 Boehringer Ingelheim International GmbH Novel and selective ccr2 antagonists
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
US20140329809A1 (en) 2011-10-28 2014-11-06 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
PH12020551186B1 (en) 2012-11-15 2024-03-20 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
RS62867B1 (sr) 2013-03-06 2022-02-28 Incyte Holdings Corp Postupci i intermedijeri za dobijanje inhibitora jak
US20160045617A1 (en) * 2013-04-10 2016-02-18 Justin C. Lee Treatment of proximal spinal muscular atrophy
GB201309508D0 (en) * 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
GB201311953D0 (en) * 2013-07-03 2013-08-14 Redx Pharma Ltd Compounds
SMT202000315T1 (it) 2013-08-07 2020-07-08 Incyte Corp Forme di dosaggio a rilascio prolungato per un inibitore di jak1
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
WO2016128343A1 (en) * 2015-02-09 2016-08-18 F. Hoffmann-La Roche Ag Compounds for the treatment of cancer
EP3053577A1 (en) * 2015-02-09 2016-08-10 F. Hoffmann-La Roche AG Compounds for the treatment of cancer
PT3317270T (pt) 2015-07-02 2020-08-24 Centrexion Therapeutics Corp (4-((3r,4r)-3-metoxitetrahidro-pirano-4-ilamino)piperidina-1-il)(5-metil-6-(((2r,6s)-6-(p-tolil)tetrahidro-2h-pirano-2-il)metilamino)pirimidina-4-il)citrato de metanona
CN112480079B (zh) * 2017-11-08 2022-03-11 北京嘉林药业股份有限公司 化合物及其治疗癌症的用途
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
SG11202007164UA (en) 2018-01-30 2020-08-28 Incyte Corp Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
SMT202400306T1 (it) 2018-03-30 2024-09-16 Incyte Corp Trattamento dell'idrosadenite suppurativa utilizzando inibitori di jak.
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
EP4329881A4 (en) * 2021-04-30 2025-06-11 Vanqua Bio, Inc. Small molecule modulators of glucocerebrosidase activity and uses thereof
AU2023296161A1 (en) 2022-06-13 2025-01-02 Alivexis, Inc. Azacycloalkyl carbonyl cyclic amine compound

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032526A (en) 1975-10-02 1977-06-28 American Cyanamid Company 1,2-dimethyl-3 or 5-piperazinyl-pyrazolium salts
US4426382A (en) 1980-02-13 1984-01-17 Sankyo Company Limited 4-Amino-6,7-dimethoxy-2-piperazinylquinazoline derivatives, their preparation and use
DE3517617A1 (de) 1985-05-15 1986-11-20 Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München Neue pyridaziniumverbindungen, verfahren zu deren herstellung und diese enthaltende fungizide und algizide mittel
ES8802151A1 (es) * 1985-07-31 1988-04-01 Janssen Pharmaceutica Nv Un procedimiento para la preparacion de nuevos piridazinaminas.
DE69325662T2 (de) 1992-10-23 2000-02-10 Merck Sharp & Dohme Ltd., Hoddesdon Dopamin rezeptor subtyp liganden
JP3166376B2 (ja) 1993-02-03 2001-05-14 松下電器産業株式会社 熱利用装置
US5629325A (en) 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US6514977B1 (en) * 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
US6979686B1 (en) * 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
JPH1190106A (ja) * 1997-09-26 1999-04-06 Daicel Chem Ind Ltd 擬似移動床式クロマト分離装置
EE04588B1 (et) 1997-10-27 2006-02-15 Neurosearch A/S Heteroarüüldiasatsükloalkaanid kui atsetüülkoliini nikotiinretseptorite kolinergilised ligandid, nende kasutamine ravimitena ning neid sisaldav farmatseutiline kompositsioon
US6143892A (en) * 1998-11-20 2000-11-07 G. D. Searle & Co. Process for making 5-substituted pyrazoles
US6248755B1 (en) 1999-04-06 2001-06-19 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
EP1046593A1 (en) * 1999-04-12 2000-10-25 Heineken Technical Services B.V. Closure for container
SK287418B6 (sk) 1999-05-04 2010-09-07 Schering Corporation Farmaceutický prípravok s obsahom CCR5 antagonistov a súprava s obsahom tohto prípravku
OA12274A (en) 2000-05-22 2006-05-09 Aventis Pharma Inc Arylmethylamine derivatives for use as tryptase inhibitors.
WO2003037271A2 (en) 2001-10-30 2003-05-08 Millennium Pharmaceuticals,Inc. Compounds, pharmaceutical compositions and methods of use therefor
US6806279B2 (en) 2001-12-17 2004-10-19 Sunesis Pharmaceuticals, Inc. Small-molecule inhibitors of interleukin-2
EP1474401A2 (en) * 2002-02-05 2004-11-10 Novo Nordisk A/S Novel aryl- and heteroarylpiperazines
HUP0200849A2 (hu) 2002-03-06 2004-08-30 Sanofi-Synthelabo N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
CN100445276C (zh) * 2002-03-13 2008-12-24 詹森药业有限公司 用作组蛋白去乙酰酶抑制剂的磺酰基衍生物
US20040014744A1 (en) 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
TW200400960A (en) 2002-06-05 2004-01-16 Pharmacia Corp Novel pyrazoles and their use as P38 kinase inhibitors
AU2003270199A1 (en) 2002-09-13 2004-04-30 Glaxo Group Limited Urea compounds active as vanilloid receptor antagonists for the treatment of pain
GB0229618D0 (en) * 2002-12-19 2003-01-22 Cancer Rec Tech Ltd Pyrazole compounds
WO2004074438A2 (en) 2003-02-14 2004-09-02 Smithkline Beecham Corporation Ccr8 antagonists
PL1633724T3 (pl) 2003-03-12 2011-10-31 Kudos Pharm Ltd Pochodne ftalazynonu
CA2523431A1 (en) * 2003-04-23 2004-11-25 Glaxo Group Limited Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases
FR2854158B1 (fr) 2003-04-25 2006-11-17 Sanofi Synthelabo Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique
JP2006528147A (ja) 2003-07-18 2006-12-14 グラクソ　グループ　リミテッド ヒスタミンｈ３受容体リガンドとしての置換ピペリジン
WO2005009976A1 (en) 2003-07-29 2005-02-03 Novo Nordisk A/S Pyridazinyl- piperazines and their use as histamine h3 receptor ligands
KR20080052683A (ko) * 2003-12-18 2008-06-11 인사이트 코포레이션 케모킨 수용체의 조절제로서의3-사이클로알킬아미노피롤리딘 유도체
US7435830B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US7423147B2 (en) 2004-03-31 2008-09-09 Janssen Pharmaceutical, N.V. Pyridine compounds as histamine H3 modulators
WO2005117909A2 (en) 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
WO2006001958A2 (en) 2004-05-21 2006-01-05 Merck & Co., Inc. Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity
CA2569016C (en) 2004-06-02 2012-11-27 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
WO2006012135A1 (en) 2004-06-24 2006-02-02 Janssen Pharmaceutica, N. V. Quaternary salt ccr2 antagonists
US8071624B2 (en) 2004-06-24 2011-12-06 Incyte Corporation N-substituted piperidines and their use as pharmaceuticals
WO2006004741A2 (en) 2004-06-28 2006-01-12 Incyte Corporation 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
JP2008510783A (ja) 2004-08-26 2008-04-10 クドス ファーマシューティカルズ リミテッド ４−ヘテロアリールメチル置換フタラジノン誘導体
GB0420831D0 (en) 2004-09-17 2004-10-20 Glaxo Group Ltd Novel compounds
AU2005286647A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
GB0421525D0 (en) 2004-09-28 2004-10-27 Novartis Ag Inhibitors of protein kineses
WO2006038734A1 (en) * 2004-10-08 2006-04-13 Astellas Pharma Inc. Pyridazinone derivatives cytokines inhibitors
CA2589106C (en) * 2004-11-02 2015-07-21 Northwestern University Pyridazine compounds, compositions and methods and their use in treating inflammatory diseases
PA8653301A1 (es) 2004-11-22 2006-11-09 Incyte Corp Incyte Corp Sales de la n-[2-({(3r)-1-[trans-4-hidroxi-4-(6-metoxipiridin-3-il) ciclohexil)pirrolidin
DE102004061751A1 (de) * 2004-12-22 2006-07-06 Bayer Healthcare Ag Cyanoguanidin-substituierte Pyrazoline
US7906645B2 (en) * 2004-12-24 2011-03-15 Astrazeneca Ab Heterocyclic compounds as ccr2b antagonists
JP2008530211A (ja) * 2005-02-16 2008-08-07 メルク エンド カムパニー インコーポレーテッド ケモカイン受容体のモジュレーターとなる置換ピラゾール
TWI385164B (zh) 2005-02-17 2013-02-11 Astellas Pharma Inc Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate derivatives (II)
JP2008537953A (ja) 2005-04-15 2008-10-02 エラン ファーマシューティカルズ，インコーポレイテッド ブラジキニンｂ１受容体拮抗作用に有用な新規化合物
TW200716594A (en) 2005-04-18 2007-05-01 Neurogen Corp Substituted heteroaryl CB1 antagonists
EP2354140A1 (en) 2005-05-20 2011-08-10 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
MX2007015675A (es) * 2005-07-04 2008-02-20 Novo Nordisk As Antagonistas del receptor de histamina h3.
US7851474B2 (en) 2005-08-02 2010-12-14 Neurogen Corporation Dipiperazinyl ketones and related analogues
GB0517184D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
AR055203A1 (es) 2005-08-31 2007-08-08 Otsuka Pharma Co Ltd Derivados de benzotiofeno con propiedades antipsicoticas
KR101415426B1 (ko) 2005-09-27 2014-07-04 아이알엠 엘엘씨 디아릴아민-함유 화합물 및 조성물, 및 ｃ-ｋｉｔ 수용체의조절제로서의 그의 용도
JO2769B1 (en) * 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
WO2007053495A2 (en) 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of ccr2
US8067457B2 (en) 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
CN101309915A (zh) 2005-11-14 2008-11-19 Irm责任有限公司 作为lxr调节剂的化合物和组合物
WO2007084868A2 (en) 2006-01-17 2007-07-26 Kalypsys, Inc. Treatment of disorders by activation of the unfolded protein response
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
NZ570847A (en) 2006-02-28 2011-10-28 Helicon Therapeutics Inc Therapeutic compounds
WO2007105058A2 (en) * 2006-03-16 2007-09-20 Pfizer Products Inc. Pyrazole compounds
WO2007120574A2 (en) 2006-04-11 2007-10-25 Merck & Co., Inc. Diaryl substituted alkanes
US7807671B2 (en) * 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
US20100168120A1 (en) 2006-04-28 2010-07-01 Neuromedix Inc. Salts of pyridazine compounds
US20080039450A1 (en) 2006-06-22 2008-02-14 Jensen Annika J Compounds
ES2548353T3 (es) 2006-12-28 2015-10-15 Abbvie Inc. Inhibidores de poli(ADP-ribosa)polimerasa
CA2676715A1 (en) * 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
JP4785881B2 (ja) 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
JP5603770B2 (ja) 2007-05-31 2014-10-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ２受容体拮抗薬およびその使用
MX2010002005A (es) 2007-08-22 2010-03-11 Irm Llc Derivados de 2-heteroaril-amino-pirimidina como inhibidores de cinasa.
RU2010116821A (ru) 2007-10-01 2011-11-10 Ф.Хоффманн-Ля Аг (Ch) N-гетероциклические биарильные карбоксамиды в качестве антагонистов рецептора ccr
US20090131417A1 (en) 2007-11-20 2009-05-21 Letavic Michael A Substituted pyridyl amide compounds as modulators of the histamine h3 receptor
EP2062889A1 (de) 2007-11-22 2009-05-27 Boehringer Ingelheim Pharma GmbH & Co. KG Verbindungen
US8829006B2 (en) 2007-11-22 2014-09-09 Boehringer Ingelheim International Gmbh Compounds
AU2009259496A1 (en) 2008-06-18 2009-12-23 F. Hoffmann-La Roche Ag Novel heteroaryl carboxamide derivatives
JP5693452B2 (ja) 2008-08-04 2015-04-01 シーエイチディーアイ ファウンデーション，インコーポレーテッド 特定のキヌレニン−３−モノオキシゲナーゼインヒビター、医薬組成物およびそれらの使用方法
GB0815369D0 (en) 2008-08-22 2008-10-01 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
AU2009289378A1 (en) 2008-09-02 2010-03-11 Boehringer Ingelheim International Gmbh Novel benzamides, production thereof, and use thereof as medicaments
CN102256963B (zh) 2008-12-19 2014-06-11 贝林格尔.英格海姆国际有限公司 作为ccr2受体拮抗剂用于治疗炎症、哮喘和copd的环状嘧啶-4-甲酰胺
US20110301143A1 (en) * 2009-02-23 2011-12-08 Elise Isabel Heterocyclic derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
ES2674275T3 (es) 2009-12-17 2018-06-28 Centrexion Therapeutics Corporation Antagonistas del receptor CCR2 y usos de los mismos
EP2513086B1 (en) 2009-12-17 2015-04-29 Boehringer Ingelheim International GmbH Novel antagonists for ccr2 and uses thereof
JP5646736B2 (ja) 2010-05-12 2014-12-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ｃｃｒ２受容体アンタゴニスト、これらの製造方法、及び薬物としてのこれらの使用
WO2011141474A1 (en) 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
WO2011144501A1 (en) 2010-05-17 2011-11-24 Boehringer Ingelheim International Gmbh Ccr2 antagonists and uses thereof
WO2011147772A1 (en) 2010-05-25 2011-12-01 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists
US8962656B2 (en) 2010-06-01 2015-02-24 Boehringer Ingelheim International Gmbh CCR2 antagonists
WO2012171863A1 (en) 2011-06-16 2012-12-20 Boehringer Ingelheim International Gmbh New selective ccr2 antagonists
EP2731941B1 (en) 2011-07-15 2019-05-08 Boehringer Ingelheim International GmbH Novel and selective ccr2 antagonists

Also Published As

Publication number Publication date
JP2010528089A (ja) 2010-08-19
EP2155689A2 (en) 2010-02-24
WO2008145681A2 (en) 2008-12-04
JP5603770B2 (ja) 2014-10-08
CL2008001593A1 (es) 2009-09-11
US20100204209A1 (en) 2010-08-12
EP2155689B1 (en) 2015-07-08
AR066799A1 (es) 2009-09-16
TW200904434A (en) 2009-02-01
WO2008145681A3 (en) 2009-03-05
US8653262B2 (en) 2014-02-18
CA2687931A1 (en) 2008-12-04

Similar Documents

Publication Publication Date Title
CA2687931C (en) Ccr2 receptor antagonists and uses thereof
EP2816040B1 (en) Process for the production of CCR2 receptor antagonists and intermediates thereof
EP2721025B1 (en) New selective ccr2 antagonists
US9108958B2 (en) Selective CCR2 antagonists
EP2513086B1 (en) Novel antagonists for ccr2 and uses thereof
EP2569295B1 (en) New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
US8841313B2 (en) CCR2 antagonists and uses thereof
US8962656B2 (en) CCR2 antagonists
US9018212B2 (en) Pyridazine carboxamides as CCR2 receptor antagonists

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130301

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250519

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250519